Nuwellis revenue grows 14% in second quarter

• Nuwellis reported preliminary second-quarter 2026 revenue growth of 14% year over year and 20% growth for the first six months of 2026.
• The company did not disclose preliminary revenue figures.
• Nuwellis said increased adoption of its Aquadex platform and commercial execution supported revenue growth.

Nuwellis (NASDAQ:NUWE), a medical technology company focused on cardiorenal solutions, reported preliminary second-quarter 2026 revenue growth of 14% year over year and first-half 2026 revenue growth of 20%.

The company’s preliminary results show continued revenue expansion compared with the same periods in 2025, as Nuwellis reported increased adoption of its Aquadex platform.

“Our second quarter preliminary revenue results reflect continued commercial momentum and the outstanding execution of our entire Nuwellis team,” said Nuwellis Chief Executive Officer Mike McCormick.

Nuwellis said the 20% first-half revenue growth reflects increasing adoption of Aquadex, while the company plans to provide full financial results for the three and six months ended June 30, 2026, before U.S. financial markets open on August 13, 2026.

The company said it will discuss financial performance, commercial initiatives, product development programmes and strategic partnerships during its earnings call.

Nuwellis develops medical technology solutions for patients with cardiorenal conditions, including its Aquadex ultrafiltration platform designed for fluid management.

The company said it continues to focus on expanding adoption of its products and executing its long-term growth strategy through commercial initiatives, product development and partnerships.